title: Effect of hemocoagulase for prevention of pulmonary hemorrhage in critical newborns on mechanical ventilation: a randomized controlled trial.
abstract: OBJECTIVE
  To investigate the role of hemocoagulase to prevent pulmonary hemorrhage in critical newborns on mechanical ventilation.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  Neonatal Intensive Care Unit of an affiliated hospital of a Medical University.
  Seventy-two critical newborn infants on mechanical ventilation.
  
  
  METHODS
  The involved neonates were divided randomly into two groups. Forty-one patients were treated with prophylactic hemocoagulase(dripped through the endotracheal tube), and other 31 neonates served as controls.
  
  
  METHODS
  Incidence of pulmonary hemorrhage, time of ceasing pulmonary hemorrhage if occurred, time of withdrawing of mechanical ventilation in the survivors, and mortality.
  
  
  RESULTS
  The incidence of pulmonary hemorrhage (12% vs 42%) and the time of ceasing pulmonary hemorrhage (1.36 +/- 0.65 vs 3.58 +/- 0.82, days), were significantly less in infants treated with prophylactic hemocoagulase as compared with the controls (P<0.05). The time to withdrawal of mechanical ventilation was less in the intervention group (3.20 +/- 0.45 vs 5.04 +/- 1.51 days) (P < 0.05). The mortality in children who received hemocoagulase was 22.0%, which was significantly less than controls (41.9 %) (P < 0.05).
  
  
  CONCLUSIONS
  Prophylactic use of hemocoagulase in mechanically ventilated neonates is effective against pulmonary hemorrhage.
authors: Department of Pediatrics, Research Institute of Surgery and Daping Hospital, Third Military Medical University, Chongqing, China. petshi530@hotmail.com
authors: Yuan
authors: Y
authors: Shi
authors: Jinning
authors: J
authors: Zhao
authors: Shifang
authors: S
authors: Tang
authors: Feng
authors: F
authors: Pan
authors: Lei
authors: L
authors: Liu
authors: Zhaoxia
authors: Z
authors: Tian
authors: Huangqiang
authors: H
authors: Li
mesh_terms: D001034:Apgar Score; D012103:Batroxobin / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D005865:Gestational Age; D006470:Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007363:Intensive Care Units, Neonatal; D015931:Intensive Care, Neonatal / Q000379:methods*; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D012121:Respiration, Artificial
chemical_list: D006490:Hemostatics; D012103:Batroxobin